Change in body weight
At week 72, more participants on tirzepatide MTD than placebo achieved reductions in body weight of ≥10, ≥15 and ≥20% from randomization (At 72 weeks, for the TRE, 94.0% (270) of participants in the tirzepatide MTD group maintained ≥80% of body weight lost during the 12-week lead-in period compared with 43.8% (128) in the placebo group (OR 19.7; 95% CI 10.3, 37.6; Overall, for the TRE, intensive lifestyle intervention followed by 72 weeks of tirzepatide led to a total weight change of −24.3% compared with −4.5% with intensive lifestyle intervention followed by placebo (estimated treatment difference −19.9 percentage points (95% CI −23.5, −16.2) (Fig. Accordingly, there was a reduction in BMI with tirzepatide compared with placebo from randomization to week 72 (efficacy estimand: tirzepatide, −7.7 kg/m